The glucose-dependent action of fasiglifam makes it a promising candidate for a novel therapy for diabetes with a low risk of hypoglycemia, in contrast to the widely prescribed antidiabetic drug sulfonylurea, which increases insulin release regardless of glucose levels and can lead to hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.